Arcturus Therapeutics Holdings Inc. Stock News

These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering e

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company

Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming months. The Ornithine-Transcarbamylase Deficiency ma

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company

ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023.

Arcturus Therapeutics has several collaboration agreements. The company is a clinical-stage biotech.

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.98 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.82 per share a year ago.

During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirming care.

The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry's research and development. Large biotech companies such as Johnson and Johnson (NYSE: JNJ ), Me

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric

Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate for ornithine transcarbamylase deficiency. The comp

Arcturus Therapeutics (ARCT) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $2.92 per share. This compares to loss of $1.94 per share a year ago.

New Covid strain XBB.1.18, nicknamed arcturus, is quickly spreading across the U.S., but experts are warning that pink eye and high fever, two symptoms of the new variant, are particularly present amo

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023.

Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing